<p>Tourmaline Bio Inc. has completed a merger, resulting in the cancellation and conversion of all outstanding shares-excluding certain specified shares-into the right to receive the agreed merger consideration. In connection with the closing, the company also provided notice to Leerink Partners LLC of its decision to terminate the ATM Sales Agreement, which had allowed Tourmaline to offer and sell up to $100 million of its common stock through an at-the-market equity offering program. The termination of this agreement is contingent upon the completion of the merger. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tourmaline Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-102971), on October 28, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

TRML

<p>Tourmaline Bio Inc. has completed a merger, resulting in the cancellation of outstanding shares into the right to receive merger consideration. The company also terminated its $100 million ATM Sales Agreement with Leerink Partners LLC, contingent upon the merger's completion. This news is for informational purposes only and should not be considered financial or legal advice.</p>

Tourmaline Bio Inc. Completes Merger and Terminates $100 Million ATM Sales Agreement